title: [Hepatic resection after systemic chemotherapy for liver metastasis of colorectal cancer].
abstract: We report 8 cases of hepatic resection after systemic chemotherapy for metastatic colorectal cancer. Three patients had unresectable hepatic lesions, and 5 patients were given neoadjuvant chemotherapy. The mean age was 69 (range: 55-81). Five patients received an oxaliplatin based regimen, 4 patients received irinotecan based regimen and 1 patient received UFT/LV. Four patients were treated with bevacizumab, and 2 patients with cetuximab. Duration of chemotherapy was 12 weeks (the mid range of 7-90 weeks). Six patients were PR, and 2 were SD. Although 1 patient had a minor biliary fistula, no major complications were observed. The duration of postoperative hospital stay was 17 (the average range of 13-22). Our results suggest that preoperative chemotherapy for hepatic resection of metastatic colorectal cancer is safe and has no adverse effect on surgery.
authors.affiliation: Dept. of Surgery, Suita Municipal Hospital.
authors.forename: Takahiko
authors.initials: T
authors.lastname: Nishigaki
authors.forename: Yoshihito
authors.initials: Y
authors.lastname: Ide
authors.forename: Kohei
authors.initials: K
authors.lastname: Murata
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D015179:Colorectal Neoplasms / Q000473:pathology*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006498:Hepatectomy; D006801:Humans; D000077146:Irinotecan; D007902:Length of Stay; D008113:Liver Neoplasms / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D005641:Tegafur / Q000008:administration & dosage; D014498:Uracil / Q000008:administration & dosage
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D005641:Tegafur; D000068258:Bevacizumab; D014498:Uracil; D000077146:Irinotecan; D000068818:Cetuximab; D002166:Camptothecin